CINtec PLUS和cobas HPV检测用于诊断有低级别鳞状上皮内病变史的加拿大妇女的阴道镜检查:基线结果

IF 3.2
Sam Ratnam , Dan Jang , Laura Gilbert , Reza Alaghehbandan , Miranda Schell , Rob Needle , Anne Ecobichon-Morris , Peizhong Peter Wang , Mozibur Rahman , Dustin Costescu , Laurie Elit , George Zahariadis , Max Chernesky
{"title":"CINtec PLUS和cobas HPV检测用于诊断有低级别鳞状上皮内病变史的加拿大妇女的阴道镜检查:基线结果","authors":"Sam Ratnam ,&nbsp;Dan Jang ,&nbsp;Laura Gilbert ,&nbsp;Reza Alaghehbandan ,&nbsp;Miranda Schell ,&nbsp;Rob Needle ,&nbsp;Anne Ecobichon-Morris ,&nbsp;Peizhong Peter Wang ,&nbsp;Mozibur Rahman ,&nbsp;Dustin Costescu ,&nbsp;Laurie Elit ,&nbsp;George Zahariadis ,&nbsp;Max Chernesky","doi":"10.1016/j.pvr.2020.100206","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective and methods</h3><p>CINtec PLUS and cobas HPV tests were assessed for triaging women referred to colposcopy with a history of LSIL cytology. Both tests were performed at baseline using ThinPrep cervical specimens and biopsy confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+) served as the clinical endpoint.</p></div><div><h3>Results</h3><p>In all ages, (19–76 years, n = 600), 44.3% (266/600) tested CINtec PLUS positive vs. 55.2% (331/600) HPV positive (p = 0.000). Based on 224 having biopsies, sensitivity to detect CIN2+ (n = 54) was 81.5% (44/54) for CINtec PLUS vs. 94.4% (51/54) for HPV testing (p = 0.039); specificities were, 52.4% (89/170) vs. 44.1% (75/170), respectively (p = 0.129). In women ≥30 years (n = 386), 41.2% (159/386) tested CINtec PLUS positive vs. 50.8% (196/386) HPV positive (p = 0.008). Based on 135 having biopsies, sensitivity to detect CIN2+ (n = 24) was 95.8% (23/24) for both CINtec PLUS and HPV tests; specificities were, 55.0% (61/111) vs. 50.5% (56/111), respectively (p = 0.503).</p></div><div><h3>Conclusions</h3><p>For women referred to colposcopy with a history of LSIL cytology, CINtec PLUS or cobas HPV test could serve as a predictor of CIN2+ with high sensitivity, particularly in women ≥30 years. Either test can significantly reduce the number of women requiring further investigations and follow up in colposcopy clinics.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"10 ","pages":"Article 100206"},"PeriodicalIF":3.2000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2020.100206","citationCount":"4","resultStr":"{\"title\":\"CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings\",\"authors\":\"Sam Ratnam ,&nbsp;Dan Jang ,&nbsp;Laura Gilbert ,&nbsp;Reza Alaghehbandan ,&nbsp;Miranda Schell ,&nbsp;Rob Needle ,&nbsp;Anne Ecobichon-Morris ,&nbsp;Peizhong Peter Wang ,&nbsp;Mozibur Rahman ,&nbsp;Dustin Costescu ,&nbsp;Laurie Elit ,&nbsp;George Zahariadis ,&nbsp;Max Chernesky\",\"doi\":\"10.1016/j.pvr.2020.100206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective and methods</h3><p>CINtec PLUS and cobas HPV tests were assessed for triaging women referred to colposcopy with a history of LSIL cytology. Both tests were performed at baseline using ThinPrep cervical specimens and biopsy confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+) served as the clinical endpoint.</p></div><div><h3>Results</h3><p>In all ages, (19–76 years, n = 600), 44.3% (266/600) tested CINtec PLUS positive vs. 55.2% (331/600) HPV positive (p = 0.000). Based on 224 having biopsies, sensitivity to detect CIN2+ (n = 54) was 81.5% (44/54) for CINtec PLUS vs. 94.4% (51/54) for HPV testing (p = 0.039); specificities were, 52.4% (89/170) vs. 44.1% (75/170), respectively (p = 0.129). In women ≥30 years (n = 386), 41.2% (159/386) tested CINtec PLUS positive vs. 50.8% (196/386) HPV positive (p = 0.008). Based on 135 having biopsies, sensitivity to detect CIN2+ (n = 24) was 95.8% (23/24) for both CINtec PLUS and HPV tests; specificities were, 55.0% (61/111) vs. 50.5% (56/111), respectively (p = 0.503).</p></div><div><h3>Conclusions</h3><p>For women referred to colposcopy with a history of LSIL cytology, CINtec PLUS or cobas HPV test could serve as a predictor of CIN2+ with high sensitivity, particularly in women ≥30 years. Either test can significantly reduce the number of women requiring further investigations and follow up in colposcopy clinics.</p></div>\",\"PeriodicalId\":46835,\"journal\":{\"name\":\"Papillomavirus Research\",\"volume\":\"10 \",\"pages\":\"Article 100206\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.pvr.2020.100206\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Papillomavirus Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405852120300446\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Papillomavirus Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405852120300446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

摘要

目的和方法评估scintec PLUS和cobas HPV检测对有LSIL细胞学史的妇女进行阴道镜检查的分类。两项试验均在基线时使用ThinPrep宫颈标本进行,活检证实宫颈上皮内瘤变2级或更严重(CIN2+)作为临床终点。结果在所有年龄段(19 ~ 76岁,n = 600), CINtec PLUS阳性的占44.3% (266/600),HPV阳性的占55.2% (331/600)(p = 0.000)。基于224例活检,CINtec PLUS检测CIN2+的敏感性(n = 54)为81.5% (44/54),HPV检测为94.4% (51/54)(p = 0.039);特异性分别为52.4%(89/170)和44.1% (75/170)(p = 0.129)。在≥30岁的女性中(n = 386), 41.2%(159/386)检测CINtec PLUS阳性,50.8%(196/386)检测HPV阳性(p = 0.008)。基于135例活检,CINtec PLUS和HPV检测对CIN2+ (n = 24)的敏感性为95.8% (23/24);特异性分别为55.0%(61/111)和50.5% (56/111)(p = 0.503)。结论:对于有LSIL细胞学史的女性,CINtec PLUS或cobas HPV检测可作为CIN2+的高灵敏度预测因子,特别是在≥30岁的女性中。这两种检查都能显著减少需要在阴道镜诊所进行进一步检查和随访的妇女人数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings

CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings

Objective and methods

CINtec PLUS and cobas HPV tests were assessed for triaging women referred to colposcopy with a history of LSIL cytology. Both tests were performed at baseline using ThinPrep cervical specimens and biopsy confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+) served as the clinical endpoint.

Results

In all ages, (19–76 years, n = 600), 44.3% (266/600) tested CINtec PLUS positive vs. 55.2% (331/600) HPV positive (p = 0.000). Based on 224 having biopsies, sensitivity to detect CIN2+ (n = 54) was 81.5% (44/54) for CINtec PLUS vs. 94.4% (51/54) for HPV testing (p = 0.039); specificities were, 52.4% (89/170) vs. 44.1% (75/170), respectively (p = 0.129). In women ≥30 years (n = 386), 41.2% (159/386) tested CINtec PLUS positive vs. 50.8% (196/386) HPV positive (p = 0.008). Based on 135 having biopsies, sensitivity to detect CIN2+ (n = 24) was 95.8% (23/24) for both CINtec PLUS and HPV tests; specificities were, 55.0% (61/111) vs. 50.5% (56/111), respectively (p = 0.503).

Conclusions

For women referred to colposcopy with a history of LSIL cytology, CINtec PLUS or cobas HPV test could serve as a predictor of CIN2+ with high sensitivity, particularly in women ≥30 years. Either test can significantly reduce the number of women requiring further investigations and follow up in colposcopy clinics.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
14 weeks
期刊介绍: The official Journal of the International Papillomavirus Society Papillomavirus Research (PVR), the Journal of HPV and other Small DNA Tumor Viruses publishes innovative papers related to all aspects of papillomaviruses and other small DNA tumor viruses. The official journal of the International Papillomavirus Society, PVR is an open access publication that aims to bring together virologists, immunologists, epidemiologists and clinicians working in the booming field of HPV and animal papillomaviruses, polyomaviruses and other small DNA tumor viruses and their associated diseases, in order to foster and facilitate interdisciplinary communication. The journal welcomes original research articles, reviews, short communications, opinion articles and regional update reports on papillomaviruses and other tumor viruses in the following sections: a. Biology of papillomaviruses and related viruses from life cycle to cancer b. Epidemiology etiology and natural history studies c. Natural and induced immunity including vaccine research d. Intervention studies and strategies including i. Clinical studies and trials ii. HPV treatments iii. HPV vaccination programs iv. Diagnostics and screening e. Infection and disease prevention, modeling studies f. Guidelines and public health recommendations g. HPV Studies in special populations Regional and local studies on these viruses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信